Nanocapsules: A Novel Formulation Technology For Platinum-Based Anticancer Drugs

Bibliography

• Rosenberg B, Vancamp L, Krigas T: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205, 698–699 (1965).
   Google Scholar
• Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307–20 (2005).
   Google Scholar
• Douple EB: cis-Diamminedichloroplatinum( II): effects of a representative metal coordination complex on mammalian cells. Pharmacol. Ther. 25, 297–326 (1984).
   Google Scholar
• Speelmans G, Sips WH, Grisel RJ et al.: The interaction of the anticancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride ion concentration. Biochim. Biophys. Acta 1283, 60–66 (1996).
   Google Scholar
• Speelmans G, Staffhorst RW, Versluis K, Reedijk J, de Kruijff B: Cisplatin complexes with phosphatidylserine in membranes. Biochemistry 36, 10545–10550 (1997).
   Google Scholar
• el-Khateeb M, Appleton TG, Gahan LR, Charles BG, Berners-Price SJ, Bolton AM: Reactions of cisplatin hydrolytes with methionine, cysteine, and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques. J. Inorg. Biochem. 77, 13–21 (1999).
   Google Scholar
• Reedijk J: New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc. Natl Acad. Sci. USA 100, 3611–3616 (2003).
   Google Scholar
• Akaboshi M, Kawai K, Maki H, Akuta K, Ujeno Y, Miyahara T: The number of platinum atoms binding to DNA, RNA and protein molecules of HeLa cells treated with cisplatin at its mean lethal concentration. Jpn J. Cancer Res. 83, 522–526 (1992).
   Google Scholar
• Fichtinger-Schepman AM, Lohman PH, Berends F, Reedijk J, van Oosterom AT: Interactions of the antitumour drug cisplatin with DNA in vitro and in vivo. IARC Sci. Publ. 83–99 (1986).
   Google Scholar
• Dijt FJ,Fichtinger-Schepman AM, Berends F, Reedijk J: Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res. 48, 6058–6062 (1988).
   Google Scholar
• Cooley ME, Davis LE, DeStefano M, AbrahmJ: Cisplatin: a clinical review. Part ICurrent uses of cisplatin and administration guidelines. Cancer Nurs. 17, 173–184 (1994).
   Google Scholar
• Fillastre JP, Raguenez-Viotte G: Cisplatin nephrotoxicity. Toxicol. Lett. 46, 163–175 (1989).
   Google Scholar
• Ma J, Verweij J, Kolker HJ, van Ingen HE, Stoter G, Schellens JH: Pharmacokineticdynamic relationship of cisplatin in vitro: simulation of an intravenous. bolus and 3 h and 20 h infusion. Br. J. Cancer 69, 858–862 (1994).
   Google Scholar
• Schellens JH, Ma J, Planting AS et al.: Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br. J. Cancer 73, 1569–1575 (1996).
   Google Scholar
• Wernyj RP, Morin PJ: Molecular mechanisms of platinum resistance: still searching for the Achilles’ heel. Drug Resist. Updat. 7, 227–232 (2004).
   Google Scholar
• Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265–7279 (2003).
   Google Scholar
• Connors TA, Jones M, Ross WC, Braddock PD, Khokhar AR, Tobe ML: New platinum complexes with anti-tumour activity. Chem. Biol. Interact. 5, 415–424 (1972).
   Google Scholar
• Bloemink MJ, Reedijk J: Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding. Met. Ions Biol. Syst. 32, 641–685 (1996).
   Google Scholar
• Harrap KR: Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. 12(Suppl. A), 21–33 (1985).
   Google Scholar
• van der Vijgh WJ: Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet. 21, 242–261 (1991).
   Google Scholar
• Extra JM, Espie M, Calvo F, Ferme C, Mignot L, M Marty: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25, 299–303 (1990).
   Google Scholar
• Extra JM, Marty M, Brienza S, Misset JL: Pharmacokinetics and safety profile of oxaliplatin. Semin. Oncol. 25, 13–22 (1998).
   Google Scholar
• Barnes KR, Lippard SJ: Cisplatin and related anticancer drugs: recent advances and insights. Met. Ions Biol. Syst. 42, 143–177 (2004).
   Google Scholar
• Mishima M, Samimi G, Kondo A, Lin X, Howell SB: The cellular pharmacology of oxaliplatin resistance. Eur. J. Cancer 38, 1405–1412 (2002).
   Google Scholar
• Cassidy J, Misset JL: Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. 29, 11–20 (2002).
   Google Scholar
• Takigawa N, Segawa Y, Ueoka H et al.: Combination of nedaplatin and vindesine for treatment of relapsed or refractory nonsmall- cell lung cancer. Cancer Chemother. Pharmacol. 46, 272–278 (2000).
   Google Scholar
• McKeage MJ, Higgins JD 3rd, Kelland LR: Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23–26th January 1991. Br. J. Cancer 64(4), 788–792 (1991).
   Google Scholar
• Kim NK, Kim TY, Shin SG et al.: A Phase I study of cis-malonato[(4R,5R)- 4,5-bis(aminomethyl)-1,3-dioxolane] platinum(II) in patients with advanced malignancies. Cancer 91, 1549–1556 (2001).
   Google Scholar
• Gabizon AA, Shmeeda H, Zalipsky S: Pros and cons of the liposome platform in cancer drug targeting. J. Liposome Res. 16, 175–183 (2006).
   Google Scholar
• Forssen EA, Male-Brune R, Adler-Moore JP et al.: Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue. Cancer Res. 56, 2066–2075 (1996).
   Google Scholar
• Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT: Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J. Drug Target. 10, 539–548 (2002).
   Google Scholar
• Gabizon AA: Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19, 424–436 (2001).
   Google Scholar
• Hussein M: Pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone as first-line therapy for multiple myeloma. Clin. Lymphoma 4(Suppl. 1), S18–S22 (2003).
   Google Scholar
• Leonetti C, Scarsella M, Semple SC et al.: In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors. Int. J. Cancer 110, 767–774 (2004).
   Google Scholar
• Koshkina NV, Kleinerman ES, Waidrep C et al.: 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. Clin. Cancer Res. 6, 2876–2880 (2000).
   Google Scholar
• Verschraegen CF, Gilbert BE, Huaringa AJ et al.: Feasibility, Phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)- camptothecin in patients with advanced malignancies in the lungs. Ann. NY Acad. Sci. 922, 352–354 (2000).
   Google Scholar
• Colbern GT, Dykes DJ, Engbers C et al.: Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin. Cancer Res. 4, 3077–3082 (1998).
   Google Scholar
• Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA: Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 43, 1–7 (1999).
   Google Scholar
• Peleg-Shulman T, Gibson D, Cohen R, Abra R, Barenholz Y: Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim. Biophys. Acta 1510, 278–291 (2001).
   Google Scholar
• Miller CR, Bondurant B, McLean SD, McGovern KA, O’Brien DF: Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37, 12875–12883 (1998).
   Google Scholar
• Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145–160 (2005).
   Google Scholar
• Harrington KJ, Lewanski CR, Northcote AD et al.: Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann. Oncol. 12, 493–496 (2001).
   Google Scholar
• Meerum Terwogt JM, Groenewegen G, Pluim D et al.: Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother. Pharmacol. 49, 201–210 (2002).
   Google Scholar
• Vail DM, Kurzman ID, Glawe PC et al.: STEALTH liposome-encapsulated cisplatin (SPI-77) versus carboplatin as adjuvant therapy for spontaneously arising osteosarcoma (OSA) in the dog: a randomized multicenter clinical trial. Cancer Chemother. Pharmacol. 50, 131–136 (2002).
   Google Scholar
• Zamboni WC, Gervais AC, Egorin MJ et al.: Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother. Pharmacol. 53, 329–336 (2004).
   Google Scholar
• Boulikas T: Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol. Rep. 12, 3–12 (2004).
   Google Scholar
• Stathopoulos GP, Boulikas T, Vougiouka M et al.: Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): Phase I study. Oncol. Rep. 13, 589–595 (2005).
   Google Scholar
• Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J: Liposomal oxaliplatin in the treatment of advanced cancer: a Phase I study. Anticancer Res. 26, 1489–1493 (2006).
   Google Scholar
• Xiao C, Qi X, Maitani Y, Nagai T: Sustained release of cisplatin from multivesicular liposomes: potentiation of antitumor efficacy against S180 murine carcinoma. J. Pharm. Sci. 93, 1718–1724 (2004).
   Google Scholar
• Bandak S, Goren D, Horowitz A, Tzemach D, Gabizon A: Pharmacological studies of cisplatin encapsulated in longcirculating liposomes in mouse tumor models. Anticancer Drugs 10, 911–920 (1999).
   Google Scholar
• Riley CM, Sternson LA: Cisplatin. In: Analytical Profiles of Drug Substances. Florey K (Ed.). Academic Press, NY, USA 78–105 (1985).
   Google Scholar
• Burger KN, Staffhorst RW, de Vijlder HC et al.: Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat. Med. 8, 81–84 (2002).
   Google Scholar
• Velinova MJ, Staffhorst RW, Mulder WJ et al.: Preparation and stability of lipidcoated nanocapsules of cisplatin: anionic phospholipid specificity. Biochim. Biophys. Acta 1663, 135–142 (2004).
   Google Scholar
• Chupin V, de Kroon AI, de Kruijff B: Molecular architecture of nanocapsules, bilayer-enclosed solid particles of cisplatin. J. Am. Chem. Soc. 126, 13816–13821 (2004).
   Google Scholar
• Ramachandran S, Quist AP, Kumar S, Lal R: Cisplatin nanoliposomes for cancer therapy: AFM and fluorescence imaging of cisplatin encapsulation, stability, cellular uptake, and toxicity. Langmuir 22, 8156–8162 (2006).
   Google Scholar
• Hamelers IH, van Loenen E, Staffhorst RW, de Kruijff B, de Kroon AI: Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin. Mol. Cancer Ther. 5, 2007–2012 (2006).
   Google Scholar
• Knox RJ, Friedlos F, Lydall DA, Roberts JJ: Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cisdiamminedichloroplatinum( II) and cisdiammine-( 1,1- cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 46, 1972–1979 (1986).
   Google Scholar
• de Kroon AI, Staffhorst RW, de Kruijff B, Burger KN: Cisplatin nanocapsules. Meth. Enzymol. 391, 118–125 (2005).
   Google Scholar
• Helleman J, Burger H, Hamelers IH et al.: Impaired cisplatin influx in an A2780 mutant cell line: Evidence for a putative, cis-configuration-specific, platinum influx transporter. Cancer Biol. Ther. 5, 943–949 (2006).
   Google Scholar